The Longevity Science Foundation has pledged to give $1 billion in funding over the next decade to projects, institutions and studies that advance healthy human longevity. The foundation, which is a nonprofit membership organization that is focused on advancing the field of human longevity by funding the research and development of medical technologies to extend the healthy human lifespan, is calling for proposals in longevity, psychedelics and aging clocks.
Numerous studies have found that psychedelics such as psilocybin, MDMA and ketamine may be useful in the treatment of mental health conditions, including addiction, depression and post-traumatic stress disorder. With regard to longevity and psychedelics, it has been proven that psilocybin and ketamine can help regrow neural connections, which may be useful in the development of therapies for aging-related neurodegenerative illnesses, including Parkinson’s disease and Alzheimer’s.
The funding call for this space, which is a joint effort between PsyMed Ventures and Longevity Science Foundation, invites interested parties to submit their proposals.
The two organizations specifically encourage applications from scientists working on projects associated with the use of new or existing psychedelics designed to delay, reverse or manage mental and brain illnesses linked to age. They are also keen on proposals on mechanisms underlying the complex effects induced by psychedelic compounds.
PsyMed Ventures cofounder Matias Serebrinsky stated that the company, which has been active in the psychedelic space for a while now, was excited to work with Longevity Science Foundation to research new applications of these compounds and their benefits.
Longevity Science Foundation CEO and president Lisa Ireland added that the organization was thrilled to support researchers and visionaries focused on expanding the understanding of psychedelics, which would, in turn, help contribute to a body of knowledge that would transform brain health and longevity.
Applications for this funding call will be accepted on a rolling basis until June 30, 2023.
The other funding call is focused on the concept of aging clocks and extends to software, applications and other devices that have been designed to track an individual’s biological age. Discoveries on aging clocks and biomarkers have benefited the longevity sector greatly, especially by facilitating the development of treatments, diagnostics and more. Biomarkers help determine the biological age of an individual based on the status of tissues, cells and other systems in the body.
Aging clocks also afford researchers a way to measure the effectiveness of anti-aging treatments.
Applicants interested in this particular field have until midnight on Dec. 31, 2022, to submit their proposals for funding. Visit https://longevity.foundation/apply to submit an application.
The Longevity Science Foundation joins a long list of entities, including Compass Pathways PLC (NASDAQ: CMPS), that are looking to better humanity by leveraging the medical potential of psychedelics.
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.